SENS Eversense 365 Integrated With twiist Gains Full Availability

Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its year-long wear advantage.

Zacks Investment Research • Feb 20, 2026

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes

GlobeNewsWire • Feb 19, 2026

Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365

The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes

GlobeNewsWire • Feb 19, 2026

All You Need to Know About Senseonics (SENS) Rating Upgrade to Buy

Senseonics (SENS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Feb 6, 2026

Senseonics (SENS) Moves 5.3% Higher: Will This Strength Last?

Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Feb 2, 2026

SENS Stock Up as Eversense 365 CGM Wins European CE Mark Approval

Senseonics stock jumps after Eversense 365 wins CE Mark, expanding Europe access for its one-year CGM and strengthening the long-term growth outlook.

Zacks Investment Research • Jan 30, 2026

Senseonics Receives European Approval for Eversense 365, World's Longest-lasting Continuous Glucose Monitor

GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense® 365 CGM system.

GlobeNewsWire • Jan 29, 2026

SENS Stock Up as Eversense 365 Enters AID Market With twiist System

Senseonics shares gain after Eversense 365 became the first one-year implantable CGM integrated with an automated insulin delivery system.

Zacks Investment Research • Jan 9, 2026

Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System

twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM

GlobeNewsWire • Jan 8, 2026

Senseonics: Eversense 365 Is A Game Changer For The CGM Industry

Senseonics Holdings earns a buy rating as Eversense 365 drives potential product-market fit and margin expansion. SENS's integration of Ascensia's commercial team and DTC investments is expected to boost revenue and gross margins above 50%. Q3 revenue grew 90% YoY, with a 42.8% gross margin and 55% YoY revenue growth guided for 2025.

Seeking Alpha • Dec 19, 2025